| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,167,705 | 4 | 100 |
| Gabay Avraham | Chief Financial Officer | 0 | $0 | 2 | $420,944 | $-420,944 |
| Hexter Joshua | COO & CBO | 0 | $0 | 2 | $746,761 | $-746,761 |
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has …
Over the last 12 months, insiders at Oramed Pharmaceuticals Inc. have bought $0 and sold $1.17M worth of Oramed Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Oramed Pharmaceuticals Inc. have bought $415,102 and sold $543,332 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,800 shares for transaction amount of $8,398 was made by Mayer Arie (director) on 2023‑04‑04.
| 2026-10-01 | Sale | Hexter Joshua | COO & CBO | 30,000 0.0738% | $4.51 | $135,330 | -7.14% | |
| 2026-10-01 | Sale | Gabay Avraham | Chief Financial Officer | 20,000 0.0492% | $4.51 | $90,200 | -7.14% | |
| 2026-07-01 | Sale | Hexter Joshua | COO & CBO | 137,000 0.3241% | $4.46 | $611,431 | -6.07% | |
| 2026-07-01 | Sale | Gabay Avraham | Chief Financial Officer | 73,360 0.1753% | $4.51 | $330,744 | -6.07% | |
| 2023-04-04 | Mayer Arie | director | 3,800 0.01% | $2.21 | $8,398 | +30.85% | ||
| 2023-04-03 | Mayer Arie | director | 5,009 0.0129% | $2.22 | $11,120 | +27.67% | ||
| 2023-03-16 | KIDRON NADAV | President and CEO | 26,000 0.0615% | $2.04 | $53,014 | +24.27% | ||
| 2023-03-14 | Sale | Kidron Miriam | Chief Scientific Officer | 100,000 0.2466% | $2.01 | $201,000 | +29.74% | |
| 2023-03-14 | KIDRON NADAV | President and CEO | 100,000 0.2466% | $2.01 | $201,000 | +29.74% | ||
| 2023-03-14 | Rozov Yadin | director | 50,000 0.1257% | $2.05 | $102,450 | +29.74% | ||
| 2023-03-13 | Rozov Yadin | director | 20,000 0.0499% | $1.96 | $39,120 | +35.29% | ||
| 2023-01-03 | Sale | Rabinowitz Michael | Chief Commercial Officer | 13,325 0.0346% | $12.55 | $167,195 | -81.40% | |
| 2022-03-21 | Sale | RAKIN KEVIN | 10,000 0.0258% | $9.41 | $94,096 | -28.70% | ||
| 2021-11-01 | Sale | Mayer Arie | director | 3,000 0.0084% | $25.60 | $76,800 | -65.70% | |
| 2021-09-16 | Sale | RAKIN KEVIN | director | 21,100 0.0579% | $20.99 | $442,830 | -55.96% | |
| 2021-08-09 | Sale | KIDRON NADAV | President and CEO | 220,000 0.7367% | $20.11 | $4.42M | -50.46% | |
| 2019-09-09 | Sank Leonard | director | 50,000 0.2901% | $2.92 | $146,000 | +20.52% | ||
| 2019-07-18 | Sank Leonard | director | 8,994 0.0501% | $3.85 | $34,672 | -15.72% | ||
| 2019-07-17 | Sank Leonard | director | 60,040 0.3268% | $3.63 | $218,118 | -12.64% | ||
| 2019-07-16 | Sank Leonard | director | 40,000 0.2278% | $3.52 | $140,878 | -5.76% |
| Bronfeld Zeev | 10 percent owner | 5808517 13.9637% | $23.23M | 1 | 1 | |
| REGALS CAPITAL MANAGEMENT LP | 10 percent owner | 1453637 3.4945% | $5.81M | 7 | 0 | <0.0001% |
| Sank Leonard | director | 374999 0.9015% | $1.5M | 12 | 0 | +53.27% |
| Li Xiaopeng | director | 206350 0.4961% | $825,400.00 | 2 | 0 | +13.29% |
| KIDRON NADAV | President and CEO | 126000 0.3029% | $504,000.00 | 7 | 2 | +24.34% |
| Rozov Yadin | director | 86500 0.2079% | $346,000.00 | 2 | 0 | +32.52% |
| Mayer Arie | director | 26809 0.0644% | $107,236.00 | 2 | 1 | +29.26% |
| JACOB HAROLD | director | 16396 0.0394% | $65,584.00 | 1 | 2 | <0.0001% |
| Friedman Aviad | director | 12191 0.0293% | $48,764.00 | 1 | 0 | <0.0001% |
$6,788,859 | 35 | 26.72% | $151.54M | |
Oramed Pharmaceuticals Inc. (ORMP) | $7,147,964 | 34 | 24.77% | $166.39M |
$38,621,826 | 31 | 1.43% | $157.74M | |
$41,526,694 | 30 | 23.89% | $135.61M | |
$74,231,875 | 30 | 40.62% | $183.78M |
| Increased Positions | 25 | +46.3% | 3M | +27.6% |
| Decreased Positions | 17 | -31.48% | 702,505 | -7.62% |
| New Positions | 13 | New | 2M | New |
| Sold Out Positions | 7 | Sold Out | 9,595 | Sold Out |
| Total Postitions | 62 | +14.81% | 11M | +19.98% |
| Bml Capital Management, Llc | $9,217.00 | 7.92% | 3.17M | +83,978 | +2.72% | 2025-09-30 |
| Murchinson Ltd. | $5,097.00 | 4.38% | 1.75M | 0 | 0% | 2025-09-30 |
| Boothbay Fund Management, Llc | $2,460.00 | 2.11% | 845,391 | 0 | 0% | 2025-09-30 |
| Rathbones Group Plc | $678.00 | 0.58% | 233,018 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $436.00 | 0.37% | 149,667 | +6,261 | +4.37% | 2025-09-30 |
| Renaissance Technologies Llc | $433.00 | 0.37% | 148,900 | +4,700 | +3.26% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $429.00 | 0.37% | 147,487 | -19,412 | -11.63% | 2025-09-30 |
| Wells Fargo & Company/Mn | $379.00 | 0.33% | 130,086 | +109,100 | +519.87% | 2025-09-30 |
| Citadel Advisors Llc | $325.00 | 0.28% | 111,707 | +24,391 | +27.93% | 2025-09-30 |
| Blackrock, Inc. | $319.00 | 0.27% | 109,733 | +24,163 | +28.24% | 2025-09-30 |